Production of Hyperimmune Anti-SARS-CoV-2 Intravenous Immunoglobulin from Pooled COVID-19 Convalescent Plasma

References

• Wang D , HuB , HuCet al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA323(11), 1061–1069 (2020).
   PubMed Web of Science ®Google Scholar
• Huang C , WangY , LiXet al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet395(10223), 497–506 (2020).
   PubMed Web of Science ®Google Scholar
• Rothan HA , ByrareddySN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun.109, 1024332020).
   PubMed Web of Science ®Google Scholar
• World Health Organization . Coronavirus disease (COVID-19) pandemic (2020). www.who.int/emergencies/diseases/novel-coronavirus-2019
   Google Scholar
• Fernandes N . Economic effects of coronavirus outbreak (COVID-19) on the world economy. IESE Business School Working Paper No. WP-1240-E. doi:10.2139/ssrn.3557504 (2020) ( Epub ahead of print)
   Google Scholar
• Cunningham AC , GohHP , KohD. Treatment of COVID-19: old tricks for new challenges. Critical Care24(1), 91 (2020).
   PubMed Web of Science ®Google Scholar
• Kim JH , MarksF , ClemensJD . Looking beyond COVID-19 vaccine phase 3 trials. Nat. Med.1–7 (2021).
   PubMed Web of Science ®Google Scholar
• Chen L , XiongJ , BaoL , ShiY. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect. Dis.20(4), 398–400 (2020).
   PubMed Web of Science ®Google Scholar
• Tanne JH . Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ368, m12562020).
   PubMed Web of Science ®Google Scholar
• Shen C , WangZ , ZhaoFet al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA323(16), 1582–1589 (2020).
   PubMed Web of Science ®Google Scholar
• Chai KL , ValkSJ , PiechottaVet al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review. Cochrane Database Syst.Rev.10, CD0136002020).
   PubMedGoogle Scholar
• Cao W , LiuX , BaiTet al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect. Dis.7(3),ofaa102 (2020).
   PubMed Web of Science ®Google Scholar
• Xie Y , CaoS , LiQet al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J. Infect.81(2), 318–3562020).
   PubMed Web of Science ®Google Scholar
• Salazar G , ZhangN , FuTMet al. Antibody therapies for the prevention and treatment of viral infections. NPJ Vaccines2, 19 (2017).
   PubMed Web of Science ®Google Scholar
• De Alwis R , ChenS , GanES , OoiEE. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development. EBioMedicine55, 1027682020).
   PubMed Web of Science ®Google Scholar
• León G et al. Industrial Production and Quality Control of Snake Antivenoms. In: Toxinology. GopalakrishnakoneP, CalveteJ. ( Eds). Springer, Dordrecht (2014).
   Google Scholar
• El-Ekiaby M , VargasM , SayedMet al. Minipool caprylic acid fractionation of plasma using disposable equipment: a practical method to enhance immunoglobulin supply in developing countries. PLoS Negl. Trop. Dis.9(2), (2015).
   PubMed Web of Science ®Google Scholar
• Morais V , BerasainP , MassaldiH. Immunoglobulin purification by caprylic acid. Protein Downstream Processing.Humana Press, NJ, USA137–143 (2014).
   Google Scholar
• Laemmli, U. K . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227(5259), 680–685 (1970).
   PubMed Web of Science ®Google Scholar
• U.S. Pharmacopeia . USP-71,Sterility tests. United States Pharmacopeia and National Formulary.USP 41-NF 36 U.S. Pharmacopeial Convention, MD, USA, 5984–5991 (2018).
   Google Scholar
• U.S. Pharmacopeia 41 . 151 Pyrogen Test. United States Pharmacopeial Convention, Inc. MD, USA,6083–6085 (2018).
   Google Scholar
• Keller MA , StiehmER. Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev.13(4), 602–614 (2000).
   PubMed Web of Science ®Google Scholar
• Duan K , LiuB , LiCet al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl Acad. Sci. USA117(17), 9490–9496 (2020).
   PubMed Web of Science ®Google Scholar
• Abrams-Downey A , SaabiyeJ , VidaurrazagaM. Investigational therapies for the treatment of COVID-19: updates from ongoing clinical trials. Eur. Urol. Focus6(5), 1028–1031 (2020).
   PubMedGoogle Scholar
• Nguyen AA , HabiballahSB , PlattCD , GehaRS , ChouJS , McdonaldDR. Immunoglobulins in the treatment of COVID-19 infection: proceed with caution!Clin. Immunol.216, 1084592020).
   PubMed Web of Science ®Google Scholar
• Weidner L , GänsdorferS , UnterwegerSet al. Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays. J. Clin. Virol.129, 104540,2020).
   PubMed Web of Science ®Google Scholar
• Barahona Afonso AF , JoãoCMP. The production processes and biological effects of intravenous immunoglobulin. Biomolecules6(1), 15 (2016).
   PubMed Web of Science ®Google Scholar
• Harlow ED , LaneD. Antibodies: a Laboratory Manual. Cold Spring Harbor Laboratory, NY, USA, 579 (1988).
   Google Scholar
• Alberts B , JohnsonA , LewisJ , MorganD , RaffM , KeithRoberts PW. W. W. Norton & CompanyMolecular Biology of the CellNY, USA . (2018).
   Google Scholar
• Fundenberg HH , StitesDP , CaldwellJL , WellsJV. Basic and Clinical Immunology.Lange Medical Publications, CA, USA (1976).
   Google Scholar
• Radosevich M , BurnoufT. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox. Sang.98(1), 12–28 (2010).
   PubMed Web of Science ®Google Scholar
• Wang Z , LorenziJC , MueckschFet al. Enhanced SARS-CoV-2 neutralization by secretory IgA in vitro. bioRxiv doi:10.1101/2020.09.09.2885552020) ( Epub ahead of print).
   Google Scholar
• Parkkinen J , RaholaA , Von BonsdorffL , TölöH , TörmäE. A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance. Vox. Sang.90(2), 97–104 (2006).
   PubMed Web of Science ®Google Scholar
• Kothe N , RudnickD , PiechaczekD , KleinH , RohmD , KloftM ( Manufacturing intravenous tolerable immunoglobulin-g preparation US5164487AUnited States1992).
   Google Scholar
• Vargas M , SeguraA , WuYWet al. Human plasma‐derived immunoglobulin G fractionated by an aqueous two‐phase system, caprylic acid precipitation, and membrane chromatography has a high purity level and is free of detectable in vitro thrombogenic activity. Vox. Sang.108(2), 169–177 (2015).
   PubMed Web of Science ®Google Scholar
• Yang R , LanJ , HuangBet al. Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections. EBioMedicine58, 1028902020).
   PubMed Web of Science ®Google Scholar
• Abolhassani H , AsgardoonMH , RezaeiN , HammarstromL , AghamohammadiA. Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient?. Expert. Rev. Clin. Immunol.11(11), 1229–1243 (2015).
   PubMed Web of Science ®Google Scholar
• Ochiai M , YamamotoA , NaitoSet al. Applicability of bacterial endotoxins test to various blood products by the use of endotoxin-specific lysates. Biologicals38(6), 629–636 (2010).
   PubMed Web of Science ®Google Scholar